2024-11-04T16:20:00-05:00 2023-12-31 465664616 CPA DEPARTMENT 12001 SUNRISE VALLEY DR STE 303 RESTON VA 20191 990 2023-01-01 844147678 THE HIV AND HEPATITIS POLICY INSTITUTE HIVA 2024623042 1602B BELMONT ST NW WASHINGTON DC 20009 CARL E SCHMID II PRESIDENT/EXEC DIR 2027835550 2024-11-01 true true JENNIFER EUBANKS CPA P01784811 7037292882 2024-11-01 2023 2024-10-15 13:58:12Z CARL E SCHMID II 1602B BELMONT ST NW APT 2 WASHINGTON DC 20009 1313570 false X HTTPS://HIVHEP.ORG/ X 2019 DC THE HIV AND HEPATITIS POLICY INSTITUTE PROMOTES QUALITY AND AFFORDABLE HEALTHCARE FOR PEOPLE LIVING WITH OR AT RISK OF HIV, HEPATITIS, AND OTHER SERIOUS CHRONIC HEALTH CONDITIONS. 9 8 3 0 1182550 1300000 0 13570 75000 0 1257550 1313570 0 0 491187 555078 0 15452 657404 482796 1148591 1037874 108959 275696 821996 1097692 0 821996 1097692 X THE HIV+HEPATITIS POLICY INSTITUTE PROMOTES QUALITY AND AFFORDABLE HEALTHCARE FOR PEOPLE LIVING WITH OR AT RISK OF HIV, HEPATITIS, AND OTHER SERIOUS AND CHRONIC HEALTH CONDITIONS. MONITORS POLICIES THAT IMPACT THE PREVENTION AND TREATMENT OF HIV, VIRAL HEPATITIS, AND OTHER HEALTH CONDITIONS IN THE UNITED STATES. COMMUNICATES WITH MEMBERS OF THE HIV, HEPATITIS, AND OTHER PATIENT GROUP COMMUNITIES ON KEY POLICY ISSUES THAT IMPACT THEIR ACCESS TO HEALTHCARE. EDUCATES POLICYMAKERS AND MEMBERS OF THE MEDIA ABOUT EFFORTS TO END BOTH HIV AND HEPATITIS IN THE UNITED STATES AND TO IMPROVE ACCESS TO QUALITY AND AFFORDABLE HEALTHCARE FOR PEOPLE WITH OR AT RISK OF SERIOUS OR CHRONIC HEALTH CONDITIONS. false false 408546 HIV: HIV+HEP CARRIED OUT ACTIVITIES THAT ADVANCE POLICIES AND PROGRAMS THAT INCREASE HIV PREVENTION AND TREATMENT, INCLUDING THE RYAN WHITE HIV/AIDS PROGRAM AND THE ACTIVITIES OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION HIV DIVISION. AS THE FEDERAL GOVERNMENT CONTINUES TO FOCUS ON ACTIVITIES TO END HIV IN THE UNITED STATES, HIV+HEP PARTICIPATED IN ONGOING OPPORTUNITIES TO DEVELOP AND IMPLEMENT THE PROGRAMS AND POLICIES TO ACHIEVE THE GOALS OF THE INITIATIVE. ONE AREA OF FOCUS WAS PRE-EXPOSURE PROPHYLAXIS (PREP), A DRUG THAT PREVENTS HIV, INCLUDING PRIVATE INSURANCE COVERAGE, ZERO PATIENT COST-SHARING OBLIGATIONS BY INSURERS, AND THE CREATION OF A NATIONAL PREP PROGRAM. WE CONTINUED TO ENGAGE A MODELING FIRM TO UPDATE THE IMPACT ON REDUCING HIV INFECTIONS BASED ON USING AN INCREASED UPTAKE OF LONG-ACTING VERSUS ORAL DRUGS. WE ALSO RESPONDED TO MANY COMPLAINTS BY PREP USERS WHO WERE BEING ILLEGALLY CHARGED COST-SHARING FOR PREP OR THE ASSOCIATED LABS AND HELPED THEM WITH THEIR INSURERS AND REGULATORS. WE BROUGHT THIS ONGOING ISSUE TO POLICYMAKERS AND THE MEDIA. WE ALSO MONITORED A LEGAL CASE THAT CHALLENGED THE PREVENTIVE SERVICES COVERAGE REQUIREMENTS INCLUDED IN THE AFFORDABLE CARE ACT AND SUBMITTED AN AMICUS BRIEF THAT OVER 30 HIV AND HEPATITIS ORGANIZATIONS SIGNED ONTO. HIV+HEP WORKED TO ENSURE ACCESS TO ALL ANTIRETROVIRALS TO TREAT HIV IN THE MEDICARE PART D PROGRAM AND THE PRIVATE INSURANCE MARKET. WE REVIEWED INSURANCE BENEFIT DESIGN TO ENSURE PLANS WERE COMPLIANT WITH THE ACA. AS PART OF ALL ITS WORK IT ENSURED THAT THE POLICIES AND PROGRAM BEST MEET THE NEEDS OF THOSE HIGHLY IMPACTED BY HIV INCLUDING GAY MEN, TRANSGENDER WOMEN, BLACKS AND LATINOS, DRUG USERS, AND THE POOR. HIV+HEP SPOKE AT NUMEROUS HIV MEETINGS AND WEBINARS, SUBMITTED PUBLIC COMMENTS AND TESTIMONY, ISSUED PRESS RELEASES, RESPONDED TO MEDIA INQUIRIES, AND CONDUCTED OTHER MEDIA ACTIVITIES. THIS WORK WAS CONDUCTED ON ITS OWN AND IN COALITION WITH OTHERS, INCLUDING THE WORKGROUPS OF THE FEDERAL AIDS POLICY PARTNERSHIP. 123328 HEPATITIS: HIV+HEP CARRIED OUT ACTIVITIES THAT ADVANCE POLICIES AND PROGRAMS THAT INCREASE VIRAL HEPATITIS PREVENTION AND TREATMENT, INCLUDING THE ACTIVITIES OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION VIRAL HEPATITIS DIVISION. THE PRINCIPAL FOCUS OF HIV+HEP'S ACTIVITIES WAS TO ENSURE THERE ARE SUFFICIENT RESOURCES FOR STATES AND COMMUNITY-BASED ORGANIZATIONS TO OFFER HEPATITIS TESTING, CONDUCT SURVEILLANCE, AND LINK PEOPLE WITH HEPATITIS TO HEALTHCARE AND THE TREATMENT THEY NEED TO MAINTAIN THEIR HEALTH OR IN THE CASE OF HEPATITIS C, TO BE CURED. HIV+HEP OFFERED COMMENTS ON THE ADMINISTRATION'S PROPOSAL TO END HEPATITIS C. HIV+HEP SUBMITTED PUBLIC COMMENTS AND TESTIMONY, ISSUED PRESS RELEASES, RESPONDED TO MEDIA INQUIRIES AND CONDUCTED OTHER MEDIA ACTIVITIES. SINCE MANY PEOPLE IMPACTED BY HEPATITIS ARE INJECTED DRUGS USERS, HIV+HEP ALSO FOCUSED ON THEIR NEEDS AND OTHERS ASSOCIATED WITH THE OPIOID EPIDEMIC. THIS WORK WAS CONDUCTED ON ITS OWN AND IN COALITION WITH OTHERS, INCLUDING THE HEPATITIS APPROPRIATIONS COALITION. 378262 GENERAL HEALTHCARE ACCESS: HIV+HEP WORKED TO ENSURE PEOPLE LIVING WITH SERIOUS AND CHRONIC HEALTH CONDITIONS HAVE ACCESS TO AFFORDABLE HEALTHCARE, INCLUDING PRESCRIPTION DRUGS. THIS INCLUDED POLICY ANALYSIS IN THE AREAS OF MEDICAID, MEDICARE, AND PRIVATE INSURANCE. HIV+HEP EDUCATED THE PATIENT COMMUNITY, THE MEDIA, AND POLICYMAKERS AT THE FEDERAL AND STATE LEVELS, ON THE IMPORTANCE OF COPAY ASSISTANCE FOR PRESCRIPTION DRUGS. WE CONTINUED TO PARTICIPATE IN OUR LEGAL CHALLENGE OF THE FEDERAL REGULATION THAT ALLOWS INSURERS TO IMPLEMENT COPAY ACCUMULATOR PROGRAMS. HIV+HEP ALSO PARTICIPATED IN THE ACTIVITIES OF THE NATIONAL ASSOCIATION OF INSURANCE COMMISSIONERS, WHERE WE FOCUSED ON THE IMPACT OF PHARMACY BENEFIT MANAGERS ON PATIENT ACCESS AND AFFORDABILITY OF PRESCRIPTION DRUGS, PRIOR AUTHORIZATION PROCESSES AND COVERAGE OF PREVENTIVE SERVICES. HIV+HEP SUBMITTED COMMENTS ON PROPOSED EXECUTIVE AGENCY REGULATIONS, ISSUED PRESS RELEASES AND RESPONDED TO MEDIA INQUIRIES, AND PRESENTED BEFORE PATIENT GROUPS. THIS WORK WAS PERFORMED ON ITS OWN AND IN COALITION WITH OTHER PATIENT GROUPS, INCLUDING THE PARTNERSHIP FOR PART D, MEDICARE ACCESS FOR PATIENTS RX (MAPRX), AND ALL COPAYS COUNT COALITION. 910136 true true false true false false false false false false false false false false false false false false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 3 0 3 true false false false false false false false false X 9 8 false false false false false false false true true false false true true true true false false true false false X CARL E SCHMID II 2024623042 1602B BELMONT ST NW APT 2 WASHINGTON DC 20009 CARL E SCHMID II PRESIDENT/EX 60.00 X X 256758 0 48243 KEVIN HERWIG HEALTH POLIC 40.00 X 125000 0 16963 ERIN DARLING DIRECTOR X 0 0 0 MARC MEACHEM DIRECTOR X 0 0 0 JUSTIN C SMITH MS MPH SECRETARY/DI X X 0 0 0 RAFAELE NARVAEZ DIRECTOR X 0 0 0 REKHA RAMESH TREASURER/DI X X 0 0 0 ANDREW SPERLING VICE PRESIDE X 0 0 0 PAM TRAXEL DIRECTOR X 0 0 0 STEVEN R YOUNG DIRECTOR X 0 0 0 381758 65206 2 false true false KEYBRIDGE COMMUNICATIONS LLC 1722A WISCONSIN AVE NW WASHINGTON DC 20007 PUBLIC RELATION 174000 1 755000 545000 1300000 13570 13570 1313570 13570 256758 215815 33796 7147 205721 172916 27078 5727 18471 15526 2431 514 42207 35477 5555 1175 31921 26830 4202 889 289293 289293 54266 54166 100 7732 7732 55882 54591 1291 2331 2331 1724 1724 2715 2715 4009 3820 189 21844 21844 3818 3818 DUES & SUBSCRIPTIONS 23841 5100 18741 PREP MODELING 14000 14000 MEALS 1153 758 395 OTHER SMALL EQUIPMENT 188 188 1037874 910136 112286 15452 821996 110122 987570 821996 1097692 0 0 X 821996 1097692 821996 1097692 821996 1097692 275696 X false false false X 722000 1082500 1182550 1300000 4287050 722000 1082500 1182550 1300000 4287050 562416 3724634 13570 13570 75000 75000 4375620 300 X PART II, LINE 10 PREP MODELING 75,000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 91000 91000 91000 18200 4550 72800 false 11989 13345 14600 18200 58134 87201 59947 66726 73000 91000 290673 2997 3336 3650 4550 14533 21800 SCHEDULE C, PART II-A N/A X X X false false false false false false false false false CARL E SCHMID II PRESIDENT/EXEC DIR 256758 30000 18243 305001 FORM 990 - ORGANIZATION'S MISSION THE HIV+HEPATITIS POLICY INSTITUTE PROMOTES QUALITY AND AFFORDABLE HEALTHCARE FOR PEOPLE LIVING WITH OR AT RISK OF HIV, HEPATITIS, AND OTHER SERIOUS AND CHRONIC HEALTH CONDITIONS. MONITORS POLICIES THAT IMPACT THE PREVENTION AND TREATMENT OF HIV, VIRAL HEPATITIS, AND OTHER HEALTH CONDITIONS IN THE UNITED STATES. COMMUNICATES WITH MEMBERS OF THE HIV, HEPATITIS, AND OTHER PATIENT GROUP COMMUNITIES ON KEY POLICY ISSUES THAT IMPACT THEIR ACCESS TO HEALTHCARE. EDUCATES POLICYMAKERS AND MEMBERS OF THE MEDIA ABOUT EFFORTS TO END BOTH HIV AND HEPATITIS IN THE UNITED STATES AND TO IMPROVE ACCESS TO QUALITY AND AFFORDABLE HEALTHCARE FOR PEOPLE WITH OR AT RISK OF SERIOUS OR CHRONIC HEALTH CONDITIONS. FORM 990, PAGE 2, PART III, LINE 4A HIV: HIV+HEP CARRIED OUT ACTIVITIES THAT ADVANCE POLICIES AND PROGRAMS THAT INCREASE HIV PREVENTION AND TREATMENT, INCLUDING THE RYAN WHITE HIV/AIDS PROGRAM AND THE ACTIVITIES OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION HIV DIVISION. AS THE FEDERAL GOVERNMENT CONTINUES TO FOCUS ON ACTIVITIES TO END HIV IN THE UNITED STATES, HIV+HEP PARTICIPATED IN ONGOING OPPORTUNITIES TO DEVELOP AND IMPLEMENT THE PROGRAMS AND POLICIES TO ACHIEVE THE GOALS OF THE INITIATIVE. ONE AREA OF FOCUS WAS PRE-EXPOSURE PROPHYLAXIS (PREP), A DRUG THAT PREVENTS HIV, INCLUDING PRIVATE INSURANCE COVERAGE, ZERO PATIENT COST-SHARING OBLIGATIONS BY INSURERS, AND THE CREATION OF A NATIONAL PREP PROGRAM. WE CONTINUED TO ENGAGE A MODELING FIRM TO UPDATE THE IMPACT ON REDUCING HIV INFECTIONS BASED ON USING AN INCREASED UPTAKE OF LONG-ACTING VERSUS ORAL DRUGS. WE ALSO RESPONDED TO MANY COMPLAINTS BY PREP USERS WHO WERE BEING ILLEGALLY CHARGED COST-SHARING FOR PREP OR THE ASSOCIATED LABS AND HELPED THEM WITH THEIR INSURERS AND REGULATORS. WE BROUGHT THIS ONGOING ISSUE TO POLICYMAKERS AND THE MEDIA. WE ALSO MONITORED A LEGAL CASE THAT CHALLENGED THE PREVENTIVE SERVICES COVERAGE REQUIREMENTS INCLUDED IN THE AFFORDABLE CARE ACT AND SUBMITTED AN AMICUS BRIEF THAT OVER 30 HIV AND HEPATITIS ORGANIZATIONS SIGNED ONTO. HIV+HEP WORKED TO ENSURE ACCESS TO ALL ANTIRETROVIRALS TO TREAT HIV IN THE MEDICARE PART D PROGRAM AND THE PRIVATE INSURANCE MARKET. WE REVIEWED INSURANCE BENEFIT DESIGN TO ENSURE PLANS WERE COMPLIANT WITH THE ACA. AS PART OF ALL ITS WORK IT ENSURED THAT THE POLICIES AND PROGRAM BEST MEET THE NEEDS OF THOSE HIGHLY IMPACTED BY HIV INCLUDING GAY MEN, TRANSGENDER WOMEN, BLACKS AND LATINOS, DRUG USERS, AND THE POOR. HIV+HEP SPOKE AT NUMEROUS HIV MEETINGS AND WEBINARS, SUBMITTED PUBLIC COMMENTS AND TESTIMONY, ISSUED PRESS RELEASES, RESPONDED TO MEDIA INQUIRIES, AND CONDUCTED OTHER MEDIA ACTIVITIES. THIS WORK WAS CONDUCTED ON ITS OWN AND IN COALITION WITH OTHERS, INCLUDING THE WORKGROUPS OF THE FEDERAL AIDS POLICY PARTNERSHIP. FORM 990, PAGE 2, PART III, LINE 4B HEPATITIS: HIV+HEP CARRIED OUT ACTIVITIES THAT ADVANCE POLICIES AND PROGRAMS THAT INCREASE VIRAL HEPATITIS PREVENTION AND TREATMENT, INCLUDING THE ACTIVITIES OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION VIRAL HEPATITIS DIVISION. THE PRINCIPAL FOCUS OF HIV+HEP'S ACTIVITIES WAS TO ENSURE THERE ARE SUFFICIENT RESOURCES FOR STATES AND COMMUNITY-BASED ORGANIZATIONS TO OFFER HEPATITIS TESTING, CONDUCT SURVEILLANCE, AND LINK PEOPLE WITH HEPATITIS TO HEALTHCARE AND THE TREATMENT THEY NEED TO MAINTAIN THEIR HEALTH OR IN THE CASE OF HEPATITIS C, TO BE CURED. HIV+HEP OFFERED COMMENTS ON THE ADMINISTRATION'S PROPOSAL TO END HEPATITIS C. HIV+HEP SUBMITTED PUBLIC COMMENTS AND TESTIMONY, ISSUED PRESS RELEASES, RESPONDED TO MEDIA INQUIRIES AND CONDUCTED OTHER MEDIA ACTIVITIES. SINCE MANY PEOPLE IMPACTED BY HEPATITIS ARE INJECTED DRUGS USERS, HIV+HEP ALSO FOCUSED ON THEIR NEEDS AND OTHERS ASSOCIATED WITH THE OPIOID EPIDEMIC. THIS WORK WAS CONDUCTED ON ITS OWN AND IN COALITION WITH OTHERS, INCLUDING THE HEPATITIS APPROPRIATIONS COALITION. FORM 990, PAGE 2, PART III, LINE 4C GENERAL HEALTHCARE ACCESS: HIV+HEP WORKED TO ENSURE PEOPLE LIVING WITH SERIOUS AND CHRONIC HEALTH CONDITIONS HAVE ACCESS TO AFFORDABLE HEALTHCARE, INCLUDING PRESCRIPTION DRUGS. THIS INCLUDED POLICY ANALYSIS IN THE AREAS OF MEDICAID, MEDICARE, AND PRIVATE INSURANCE. HIV+HEP EDUCATED THE PATIENT COMMUNITY, THE MEDIA, AND POLICYMAKERS AT THE FEDERAL AND STATE LEVELS, ON THE IMPORTANCE OF COPAY ASSISTANCE FOR PRESCRIPTION DRUGS. WE CONTINUED TO PARTICIPATE IN OUR LEGAL CHALLENGE OF THE FEDERAL REGULATION THAT ALLOWS INSURERS TO IMPLEMENT COPAY ACCUMULATOR PROGRAMS. HIV+HEP ALSO PARTICIPATED IN THE ACTIVITIES OF THE NATIONAL ASSOCIATION OF INSURANCE COMMISSIONERS, WHERE WE FOCUSED ON THE IMPACT OF PHARMACY BENEFIT MANAGERS ON PATIENT ACCESS AND AFFORDABILITY OF PRESCRIPTION DRUGS, PRIOR AUTHORIZATION PROCESSES AND COVERAGE OF PREVENTIVE SERVICES. HIV+HEP SUBMITTED COMMENTS ON PROPOSED EXECUTIVE AGENCY REGULATIONS, ISSUED PRESS RELEASES AND RESPONDED TO MEDIA INQUIRIES, AND PRESENTED BEFORE PATIENT GROUPS. THIS WORK WAS PERFORMED ON ITS OWN AND IN COALITION WITH OTHER PATIENT GROUPS, INCLUDING THE PARTNERSHIP FOR PART D, MEDICARE ACCESS FOR PATIENTS RX (MAPRX), AND ALL COPAYS COUNT COALITION. FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF THE INSTITUTE'S 990 IS PROVIDED TO THE FULL BOARD OF DIRECTORS FOR THEIR REVIEW PRIOR TO FILING. FORM 990, PAGE 6, PART VI, LINE 12C ANY POTENTIAL CONFLICT OF INTEREST IS DISCUSSED WITH THE FULL BOARD. FORM 990, PAGE 6, PART VI, LINE 15A THE BOARD OF DIRECTORS HAS A THREE MEMBER COMPENSATION COMMITTEE WHO DETERMINES THE SALARY OF THE EXECUTIVE DIRECTOR. THE COMMITTEE DETERMINES THE LEVEL OF COMPENSATION ON SALARY HISTORY, JOB PERFORMANCE, AND COMPARISON TO OTHER SIMILAR POSITIONS IN THE WASHINGTON DC AREA. AFTER THE COMMITTEE DELIBERATES AND COMES TO A DECISION, THEIR DECISION IS DOCUMENTED AND RELAYED TO THE EXECUTIVE DIRECTOR. FORM 990, PAGE 6, PART VI, LINE 19 MEMBERS OF THE PUBLIC CAN CONTACT THE ORGANIZATION TO RECEIVE DOCUMENTS THROUGH THE WEBSITE PORTAL VIA "CONTACT US". N/A